louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06251440: Initial Experience of Transabdominal Fetal Reduction in Nepal
Official title: Transabdominal Fetal Reduction in Higher Order Multiple Pregnancies - a Pioneer Study in Nepal
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: In Vitro Fertilization
Keywords: Fetal reduction
Multifetal gestation
In Vitro fertilization
Lead sponsor: Grande International Hospital, Nepal
Sponsor class: OTHER
First posted: 2024-02-09
Enrollment: 108
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Multifetal pregnancies referred from the obstetrics and gynecology department of our hospital, different other hospitals and in vitro fertilization (IVF) centers across the country underwent ultrasound-guided transabdominal embryo/ fetal reduction procedure between February 2018 to April 2023 in our department.

Brief summary: Multifetal pregnancies are common in in vitro fertilization. Multifetal gestation increases maternal and fetal morbidity and mortality. We perform fetal reduction in our hospital by intra-thoracic injection of potassium chloride. This manuscript is description of our initial experience.

Detailed description: Assisted reproductive technology and stimulated conception have led to an increase in the prevalence of high order multifetal pregnancies (MFPs) in recent times. MFPs are associated with high maternal and fetal complications. Fetal mortality and morbidity are due to complications of prematurity. Prevalence of pregnancy induced hypertension, pre-eclampsia, eclampsia, antepartum hemorrhage, post-partum hemorrhage, gestational diabetes and difficult deliveries are more in mother with MFP. Embryo/Fetal reduction in high order MFPs helps in prolongation of gestation. Multifetal pregnancy reduction (MFPR) is secondary prevention of the risks associated with MFP. Trans-abdominal intracardiac injection of KCl is a simple, safe and effective technique for MFPR. We are among the first few centers in Nepal doing MFPR. In this study, we are sharing our initial experience of the procedure.

Eligibility criteria: Inclusion Criteria:

* pregnant females with multifetal gestation who opt to undergo fetal reduction

Exclusion Criteria:

* who do not give consent

Primary outcomes:
measure: Transabdominal ultrasonography guided fetal reduction is safe and effective in first trimester
timeFrame: 4.5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Kathmandu
country: Nepal
facility: Prajwal Dahal
state: Bagmati
Study officials:
affiliation: Grande International Hospital
name: Sharma Poudel, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02663440: Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Glioblastoma Multiforme
Lead sponsor: Zhejiang Cancer Hospital
Sponsor class: OTHER
First posted: 2016-01-26
Enrollment: 41
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Phase II Trial of Hypofractionated Intensity Modulated Radiation Therapy(IMRT) With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor(GM-CSF) for Patients With Newly Diagnosed Glioblastoma Multiforme.


Eligibility criteria: Inclusion Criteria:

* Newly diagnosed and pathologically confirmed glioblastoma multiforme without an enhanced lesion beside the cerebrospinal fluid space on baseline magnetic resonance imaging
* Karnofsky performance status more than 60
* Normal liver, kidney, and bone marrow function.

Exclusion Criteria:

* Previous allergies to granulocyte macrophage colony stimulating factor
* Receiving radiotherapy
* Receiving other investigational agents
* Had uncontrolled intercurrent illnesses.

Primary outcomes:
measure: PFS
timeFrame: From date of treatment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: Zhejiang Cancer Hospital
state: Zhejiang
Study officials:
References:
Clinical trial NCT01766440: PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
Official title: Pharmacokinetics and Pharmacodynamics of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 14 Days Under Conditions of Maximal Use in Pediatric Subjects (2 to 12 Years of Age) With Plaque Psoriasis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Plaque Psoriasis
Lead sponsor: Galderma R&D
Sponsor class: INDUSTRY
First posted: 2013-01-11
Enrollment: 18
Sex: ALL
Minimum age (years): 2
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if the calcitriol absorption in pediatric subjects is comparable to that in adults and adolescents, with no significant impact on calcium/phosphorus metabolism.


Eligibility criteria: Inclusion Criteria:

* Male or female pediatric subjects, 2 to 12 years of age inclusive at screening
* Clinical diagnosis of plaque type psoriasis involving 3% through 35% body surface area at screening and baseline (excluding face and scalp)

Exclusion Criteria:

* Subjects with guttate or pustular psoriasis, erythrodermic psoriasis or active infection
* Vitamin D deficiency at screening
* Subjects with hypercalcemia and out of range urinary calcium/creatinine ratio at screening
* Subjects with secondary hyperparathyroidism at screening

Primary outcomes:
measure: Cmax of Calcitriol Plasma Level
timeFrame: Day 14
measure: Cmin of Calcitriol Plasma Level
timeFrame: Day 14
measure: Tmax of Calcitriol Plasma Level
timeFrame: Day 14
measure: AUC (0-6h) of Calcitriol Plasma Level
timeFrame: Day 14
measure: AUC (0-9h) of Calcitriol Plasma Level
timeFrame: Day 14
measure: AUC (0-12h) of Calcitriol Plasma Level
timeFrame: Day 14
Secondary outcomes:
Other outcomes:
Locations:
city: San Diego
country: United States
facility: Rady Children's Hospital - Pediatric and Adolescent Dermatology
state: California
city: Indianapolis
country: United States
facility: Dawes Fretzin Clinical Research Group, LLC
state: Indiana
city: Ann Arbor
country: United States
facility: University of Michigan Medical Center
state: Michigan
city: Chapel Hill
country: United States
facility: University of North Carolina Dermatology and Skin Cancer Center
state: North Carolina
city: Cincinnati
country: United States
facility: Cincinnati Children's Hospital Medical Center
state: Ohio
city: Dallas
country: United States
facility: Menter Dermatology Research Institute
state: Texas
city: San Antonio
country: United States
facility: Clinical Trials of Texas, Inc.
state: Texas
city: Seattle
country: United States
facility: Seattle Children's Hospital
state: Washington
Study officials:
affiliation: Galderma R&D, LLC
name: Michael Graeber, M.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT00141440: The Effect of Cycling Off Criteria During Pressure Support Ventilation in Chronic Obstructive Pulmonary Disease (COPD) Patients
Official title: The Effect of Cycling Off Criteria During Pressure Support Ventilation in Chronic Obstructive Pulmonary Disease (COPD) Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Chronic Obstructive Pulmonary Disease
Keywords: gas exchange
pressure support ventilation
respiratory mechanics
COPD patients
Lead sponsor: Policlinico Hospital
Sponsor class: OTHER
First posted: 2005-09-01
Enrollment: 13
Sex: ALL
Minimum age (years): 16
Maximum age (years): 90
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The investigators' aim is to study the effect of cycling off criteria during pressure support ventilation in COPD patients at two levels of PEEP and PSV.

Detailed description: In this study two levels of cycling off criteria at two levels of PEEP and PSV were tested in term of gas exchange, respiratory mechanics, work of breathing and patient comfort.

Eligibility criteria: Inclusion Criteria:

* Stable COPD patients during invasive mechanical ventilation

Exclusion Criteria:

* Hemodynamic instability,
* Paralysis

Primary outcomes:
measure: Respiratory mechanics, gas exchange
timeFrame: 2 minutes
Secondary outcomes:
measure: Comfort of breathing
timeFrame: 2 minutes
Other outcomes:
Locations:
city: Milano
country: Italy
facility: Ospedale Sacco
Study officials:
affiliation: Policlinico Hospital
name: davide chiumello, md
role: PRINCIPAL_INVESTIGATOR
affiliation: Policlinico
name: Davide Chiumello, MD
role: STUDY_CHAIR
References:
citation: Chiumello D, Polli F, Tallarini F, Chierichetti M, Motta G, Azzari S, Colombo R, Rech R, Pelosi P, Raimondi F, Gattinoni L. Effect of different cycling-off criteria and positive end-expiratory pressure during pressure support ventilation in patients with chronic obstructive pulmonary disease. Crit Care Med. 2007 Nov;35(11):2547-52. doi: 10.1097/01.CCM.0000287594.80110.34.
Clinical trial NCT00892840: Multiple-Ascending Dose Study
Official title: Placebo-Controlled, Ascending Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-820836 in Healthy Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Depression
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2009-05-05
Enrollment: 57
Sex: ALL
Minimum age (years): 21
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety and tolerability of BMS-820836 after multiple doses


Eligibility criteria: Inclusion Criteria:

* Panels 1-6: Healthy Male Subjects
* Panel 7: Females
* Ages 21 to 55, inclusive
* Body Mass Index (BMI) of 18 to 32 kg/m2, inclusive
* Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations

Exclusion Criteria:

* Any major surgery within 4 weeks of study drug administration
* History of cholecystectomy
* History of glaucoma or a confirmed intraocular pressure indicative of glaucoma at screening. (Normal IOP \<21 mmHg)
* Confirmed QTc (Fridericia) value ≥ 450 msec
* Confirmed QT ≥ 500 msec
* Confirmed PR ≥ 210 msec
* Confirmed QRS ≥ 120 msec
* Confirmed resting supine systolic blood pressure \> 140 mmHg
* Confirmed resting supine diastolic blood pressure \> 90 mmHg
* Confirmed resting heart rate \< 45 bpm or \> 100 bpm
* Orthostatic vital sign changes (ie., a decrease in systolic blood pressure from supine to standing \> 40 mmHg and an increase in heart rate from supine to standing \> 20 bpm) or symptoms of orthostasis
* History of peppermint allergies
* Exposure to any investigational drug or placebo within 12 weeks of study drug administration

Primary outcomes:
measure: To assess the safety and tolerability of BMS-820836 following multiple-dose administration
timeFrame: Within 27 days (+/- 2 days) of first dose
Secondary outcomes:
measure: To assess the pharmacodynamics of BMS-820836
timeFrame: Within 27 days of first dose
Other outcomes:
Locations:
city: Uppsala
country: Sweden
facility: Local Institution
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References:
Clinical trial NCT04639440: Impact of Adipose Tissue in COVID-19
Official title: Impact of Adipose Tissue in COVID-19 : From Pathophysiology to Therapeutic Perspectives
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Covid19
Keywords: Adipose tissue
Covid19
SARS-CoV2
Lead sponsor: Assistance Publique - Hôpitaux de Paris
Sponsor class: OTHER
First posted: 2020-11-20
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Obese and thin patients operated on for abdominal vascular surgery.

Brief summary: Overweight or obese patients are particularly exposed to severe forms of COVID-19. Few data suggest that adipose tissue infected with SARS-CoV-2 could be involved in the onset of the cytokine storm seen in severe forms of COVID-19. The aim of this study is to determine the pathogenesis of SARS-CoV-2-infection of adipose tissue. In particular the investigators will study how this virus enters the adipocyte and how it modulates metabolism and inflammation in the adipose tissue. From these data, the investigators hope to determine at the adipose tissue level, original therapeutic targets to modulate the effects of SARS-CoV-2 at the systemic level.


Eligibility criteria: Inclusion Criteria:

* Age greater than or equal to 18 years
* All patients who are obese or overweight (\> 25 kg/m2) or non-obese (\< or = 25 kg/m2) operated for abdominal vascular surgery
* Beneficiary or entitled to a social security scheme (except AME)

Exclusion Criteria:

* Pregnant or breastfeeding woman
* Patient refusal
* Patient deprived of liberty or subject to a legal protection measure (guardianship, curatorship)

Primary outcomes:
measure: Comparison of the expression of ACE2 and TMPRSS2 in the subcutaneous and visceral adipose tissue of obese patients. Determination of cells expressing ACE2 and TMPRSS2 in whole human adipose tissue.
timeFrame: 12 months
Secondary outcomes:
measure: Demonstration of entry and replication of SARS-CoV-2 in human adipose tissue
timeFrame: 12 months
measure: Consequences of infection with SARS-CoV-2 on the metabolism and inflammatory state of adipose tissue.
timeFrame: 12 months
measure: Consequences of infection with SARS-CoV-2 on the metabolism and inflammatory state of adipose tissue.
timeFrame: 12 months
measure: Effect of SARS-CoV-2 infection of adipose tissue / adipocytes from thin and obese subjects on endoplasmic reticulum (ER) homeostasis.
timeFrame: 12 months
measure: Target endoplasmic reticulum stress to reduce spread of SARS-CoV-2 from adipose tissue
timeFrame: 12 months
Other outcomes:
Locations:
city: Paris
country: France
facility: Hôpital de la Pitié Salpêtrière
Study officials:
affiliation: Hôpital Pitié Salpêtrière - Assistance Publique Hôpitaux de Paris
name: Olivier BOURRON, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02619240: Application of GeneXpert on Bronchoscopic Samples in the Clinical Management of Patients Suspicious of TB
Official title: Application of GeneXpert on Bronchoscopic Samples in the Clinical Management of Patients Suspicious of TB
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Tuberculosis
Lead sponsor: Chinese University of Hong Kong
Sponsor class: OTHER
First posted: 2015-12-02
Enrollment: 200
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: adult patients with abnormal chest imaging suspected of TB as a differential diagnosis

Brief summary: This is a case control observational study using Bronchial-alveolar lavage (BAL) as specimen for GeneXpert, a real time polymerase chain reaction (PCR) test for detection of tuberculosis (TB). Patients suspicious of TB, who require bronchoscopy as part of the investigation procedures, will be recruited for this study over a period of 18 months. Clinical likelihood of TB will be systematically scored according to various clinical parameters. This will determine the pre-test probability. Clinician will decide if anti-TB treatment is to be started and patients will be followed up for a minimal of 18 months. Sensitivity, specificity, positive, negative predictive values and the respective likelihood ratio will be calculated accordingly.


Eligibility criteria: Inclusion Criteria:

1. Patients \> 18 years old suspected of TB clinically.
2. Patients suspected of TB but both smear microscopy and TB PCR of sputum are negative or sputum cannot be produced.
3. BAL samples obtained following standard investigation procedure
4. CXR or CT imaging available.

Exclusion Criteria:

1. Bronchoscopy is not planned as a necessary procedure for investigation.
2. Diagnosis of active TB has been made by other means.

Primary outcomes:
measure: The number of true positive BAL PCR using GeneXpert on BAL for rapid diagnosis of TB in few hours compare to the conventional TB PCR which usually take up few days to perform
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Shatin
country: Hong Kong
facility: Department of Medicine and Therapeutics, Prince of Wales Hospital, CUHK
Study officials:
affiliation: Honoary clinical assistant professor
name: Kin Wang To, MBChB
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00032240: Shoe Inserts for Treating Osteoarthritis of the Knee
Official title: Randomized Trial of a Wedged Insole for Treatment of Osteoarthritis of the Knee
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Osteoarthritis, Knee
Keywords: Biomechanics
Lead sponsor: Boston University
Sponsor class: OTHER
Collaborators: name: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
First posted: 2002-03-13
Enrollment: 90
Sex: ALL
Minimum age (years): 45
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This trial will test shoe inserts for the treatment of knee osteoarthritis, the most common form of knee arthritis. Those with disease on the inner (medial) aspect of the knee will be studied.


Eligibility criteria: Inclusion Criteria:

* Medial knee osteoarthritis
* Pain
* No foot problems
* Lives in Boston, Massachusetts Metro area

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Boston University Medical Center
state: Massachusetts
Study officials:
affiliation: Boston University
name: David T. Felson, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kerrigan DC, Lelas JL, Goggins J, Merriman GJ, Kaplan RJ, Felson DT. Effectiveness of a lateral-wedge insole on knee varus torque in patients with knee osteoarthritis. Arch Phys Med Rehabil. 2002 Jul;83(7):889-93. doi: 10.1053/apmr.2002.33225.
citation: Goggins J, Baker K, Felson D. What WOMAC pain score should make a patient eligible for a trial in knee osteoarthritis? J Rheumatol. 2005 Mar;32(3):540-2.
citation: Baker K, Goggins J, Xie H, Szumowski K, LaValley M, Hunter DJ, Felson DT. A randomized crossover trial of a wedged insole for treatment of knee osteoarthritis. Arthritis Rheum. 2007 Apr;56(4):1198-203. doi: 10.1002/art.22516.
Clinical trial NCT01228240: The Efficacy of Metformin Produced by Pars Mino Co in Comparison With Canadian Apotex Co.
Official title: The Efficacy of Metformin Produced by Pars Mino Co in Comparison With Canadian Apotex Co.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Diabetes Mellitus, Type 2 AND Metformin
Keywords: Diabetes mellitus, type 2, Metformin, Generic, Efficacy
Lead sponsor: Zanjan University of Medical Sciences
Sponsor class: OTHER
First posted: 2010-10-26
Enrollment: 18
Sex: FEMALE
Minimum age (years): 30
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Background: Metformin is usually using for glycemic control in type 2 diabetes mellitus. Different pharmaceutical types of metformin are available. As a clinical trial, we compared the efficacy and complications of metformin produced by "Pars Mino pharmaceutical company, Iran" with "Apotex pharmaceutical company, Canada", in type 2 diabetic patients.

Method: 18 eligible women with type 2 diabetes were given metformin "Pars Mino" or "Apotex" (500 mg twice a day) each for 6 weeks period in a randomized, double blind, crossover study. These two groups randomly under treatment with generic metformin (manufactured by Pars Mino company) or non-generic (manufactured by Apotex Canada). After 2 weeks washout period another 6 weeks period with another Brand of metformin was prescribed. FBS, HbA1C, lipid profile (Cholesterol, TG, HDL, and LDL), weight, and BMI were assessed before and after each treatment phase. The results were compared with each other by paired sample T-test, Independent sample T-test.


Eligibility criteria: Inclusion Criteria:

* Mild hyperglycemia, no contraindication for metformin, poor controlled diabetes

Exclusion Criteria:

* Creatinine more than 1.5, severe organ damage

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06683040: Evaluation of the Efficacy and Safety of Oxacom® in Patients With Pulmonary Arterial Hypertension
Official title: A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Oxacom® in Different Dosages in Patients With Pulmonary Arterial Hypertension
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
PHASE3
Conditions: Pulmonary Arterial Hypertension
Keywords: Oxaсom
Pulmonary Arterial Hypertension
New Russian drug
Lead sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Sponsor class: OTHER_GOV
First posted: 2024-11-12
Enrollment: 260
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A multicenter, randomized, double-blind, placebo-controlled, phase II-III clinical trial to evaluate the efficacy and safety of the study drug in adult patients with pulmonary arterial hypertension (PAH).

The trial will evaluate the efficacy and safety of both single and multi-dose (seven-day) administrations of the study drug in three dosages: 0.03 mg/kg, 0.10 mg/kg, and 0.17 mg/kg.

The trial is an observer-blinded trial, since the appearance of the study drug and Placebo differs from each other. Patients included in the trial, as well as trial coordinators, investigators, and study center staff will be blinded. The only unblinded staff in the study centers will be those who preparing IP/Placebo and administering IP/Placebo to the study patients.

The trial will include 200 patients with PAH, who will be sequentially included in the trial in two stages.


Eligibility criteria: Inclusion Criteria:

* Confirmed diagnosis of PAH II or III functional class according to WHO classification
* Symptomatic PAH group 1 according to clinical classification
* Patients who have not previously received any PAH-specific therapy OR patients who have received endothelin receptor antagonists and/or iloprost/selexipag at stable doses for at least 3 months prior to the initial right heart catheterization.
* Ability to perform reproducible 6-min walking test at the screening with a distance from 150 to 450 m.

Exclusion Criteria:

* as per the study protocol

Primary outcomes:
measure: Pulmonary vascular resistance (PVR) will be measured to assess and evaluate the efficacy of study drug in comparison with placebo in patients with pulmonary arterial hypertension (PAH).
timeFrame: 6 hours after the start of the IP administration
Secondary outcomes:
Other outcomes:
Locations:
city: Moscow
country: Russian Federation
facility: NMCRCardiologyRu
Study officials:
affiliation: E.I.Chazov Cardiology Center
name: Tamila V Martynyuk, MD
role: PRINCIPAL_INVESTIGATOR
References: